About
Small Molecules, Specialty, Generics
Areas of Focus
Categories
Small Molecule PharmaceuticalGeneric DrugSoutheastern U.S.
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
84,196
By Phase
PHASE4: 3PHASE3: 1PHASE2: 1
By Status
COMPLETED: 5RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06098079Lead Sponsor
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
PHASE4Recruiting
8,600 participants
Started: Jan 3, 2024 · Completed: Jul 31, 2029
NCT03338920Lead Sponsor
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
PHASE3Terminated
159 participants
Started: Nov 2, 2017 · Completed: Apr 11, 2022
NCT02353299Lead Sponsor
Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers
PHASE4Completed
52 participants
Started: Jan 31, 2015 · Completed: Mar 31, 2016
NCT06089824Lead Sponsor
Drug Utilisation of Mysimba/Contrave
N/ACompleted
43,324 participants
Started: Sep 30, 2014 · Completed: Oct 31, 2022
NCT06090461Lead Sponsor
Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
N/ACompleted
31,889 participants
Started: Sep 30, 2014 · Completed: Dec 31, 2022
Locations (1)
Headquarters
Brentwood, TN, United States
Map
Loading map...